Mkango Resources (LON: MKA) is planning to combine its Songwe Hill rare earths project in Malawi with the Pulawy rare earth separation project in Poland and list them on Nasdaq as Mkango Rare Earths. This creates a vertically integrated rare earths business. The pro forma value of Mkango Resources’ shareholding would be $400m before any fundraising and transaction costs. The share price jumped 102% to 31p, the highest level for more than three years.
Synergia Energy (LON: SYN) plans to sell its 50% stake in the Cambay PSC Selan Exploration Technology, which owns the other 50% after a previous farm-out agreement. There will be an initial payment of $500,000 followed by $6.5m when the Indian government approves the deal. Then, 12 months later, the final $7m will be paid. This will require shareholder approval because the company will become a shell. The share price increased 42.5% to 0.0285p.
Thruvision Group (LON: THRU) has secured a contract to supply 20 security systems with a total value of £1m to a customer in Asia. In the quarter to June 2025, the order intake was £2.3m. The additional business means that the company’s cash should last until the end of 2025. After the contract announcement, Thruvision announced plans to raise at least £2.5m via a placing at 1p/share and a retail offer could raise up to £250,000. The retail offer closes on 7 July. The share price recovered 36.1% to 1.225p.
Biotech Sareum (LON: SAR) has appointed Oberon Capital as sole broker. The share price is 35.5% higher at 21p.
FALLERS
Graphene technology developer Versarien (LON: VRS) improved interim revenues from £1.34m to £1.47m and the loss was slightly lower at £1.49m. At the end of March, there was £850,000 in cash and that has fallen to £650,000. The available cash will run out by August. Later in the week, Versarien announced that it has extended its manufacturing licence agreement with Montana Quimica, which allows it to use Polygrene compounds in products sold in South America. Versarien will receive £25,000 and there is a further £25,000 when manufacturing starts and then 5% of sales revenues from those products. These payments are in addition to previous ones. The share price still slumped 53.1% to 0.015p.
Chemotherapy drug delivery technology developer CRISM Therapeutics (LON: CRTX) raised £874,000 from a placing at 12p/share and the retail offer generated £54,000. This will finance the manufacture of a batch of ChemoSeed for evaluation of safety and efficacy in glioblastoma patients in a Phase 2 registration grade clinical trial, plus setting up of clinical trials. The share price fell back 47.6% to 11p.
Online video editing technology developer Blackbird (LON: BIRD) has raised £2m from a placing and subscription at 3p/share and could raise up to £200,000 more from a retail offer. The cash will finance further development of the elevate.io platform and help to grow sales. There were 325 paid users at the end of May 2025 and the cost of adding each new user has more than halved to £115. The cost for signing up a free user is £2.14 each. Usage is increasing. The share price declined 36.3% to 3.025p.
Capital equipment supplier Mpac (LON: MPAC) has suffered from uncertainty surrounding tariffs in the US and that has stemmed the flow of orders coming through. The first half held up because of the order book at the start of the year, but there will be a slump in the second half because of a lack of new orders coming through. Outside of the US, trading is not as bad. Panmure Liberum has cut its 2025 pre-tax profit forecast from £17.9m to £13.5m with significant reductions in the following two years – which appears cautious. There will be one-off costs of restructuring the North American operations. A pension scheme buy in has been agreed with Aviva. Chief executive Adam Holland bought 3,810 shares at 262.5p each. The share price slipped 34.7% to 281p.